Victoria K Shanmugam
Washington D.C., District of Columbia, 20037, United States
NCT Number: NCT02887495
The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Observational
Washington D.C., District of Columbia, 20037, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 10 years
Time frame: 10 years
Looking for future studies?
Notify MeGeorge Washington University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06587828
Ankylosing Spondylitis, Ankylosis
Orange, California, United States
View Trial DetailsNCT06373263
Connective Tissue Diseases, Scleroderma
Montreal, Quebec, Canada
View Trial DetailsNCT06646913
Connective Tissue Diseases, Digestive System Diseases
Ann Arbor, Michigan, United States
View Trial DetailsNCT03222492
Connective Tissue Diseases, Diffuse Cutaneous Systemic Sclerosis
Los Angeles, California, United States
View Trial Details